We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes.
- Authors
Brunner, Andrew M.; Esteve, Jordi; Porkka, Kimmo; Knapper, Steve; Traer, Elie; Scholl, Sebastian; Garcia‐Manero, Guillermo; Vey, Norbert; Wermke, Martin; Janssen, Jeroen J. W. M.; Narayan, Rupa; Fleming, Shaun; Loo, Sun; Tovar, Natalia; Kontro, Mika; Ottmann, Oliver G.; Naidu, Purushotham; Sun, Haiying; Han, May; White, Roisin
- Publication
American Journal of Hematology, 2024, Vol 99, Issue 2, pE32
- ISSN
0361-8609
- Publication type
Article
- DOI
10.1002/ajh.27161